바이오X셀 테라퓨틱스BTAI 주가

BioXcel Presents New Data From Phase 3 SERENITY At-Home Trial Evaluating BXCL501 For Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia At 2026 ASCP Annual Meeting

BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced the presentation of new positive data

♻️ 재탕[4] 내부자 거래 — OWNERSHIP DOCUMENT

♻️ 재탕[4] 내부자 거래 — OWNERSHIP DOCUMENT

♻️ 재탕[4] 내부자 거래 — OWNERSHIP DOCUMENT

♻️ 재탕[4] 내부자 거래 — OWNERSHIP DOCUMENT

♻️ 재탕[144] 144

♻️ 재탕[144] 144

[144] 144

♻️ 재탕[144] 144

BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of +8.48% and -28.97%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?